Vedanta Nabs $50M

Coverage on PureTech's microbiome biotech, Vedanta Biosciences, raising $50M: "Exploration of the human microbiome has spurred countless questions about the impact the trillions of microbes in and on our bodies have on our health. Those questions have led to a growing number of new biotech companies. One of the first to launch, Vedanta Biosciences of Cambridge, MA, has [...]

June 6th, 2016|

Why Sarepta’s Shares Slumped

From Dan Caplinger/Motley Fool: "Sarepta Therapeutics plunged 27% after the Food and Drug Administration released information that could threaten the company's ability to maximize profits if its treatment for Duchenne muscular dystrophy eventually receives FDA approval. The FDA's recommendations centered on its compassionate use policy, saying companies generally could only get paid to offset its [...]

June 2nd, 2016|

Celgene, Agios in $1B+ Metabolic Immuno-Oncology Alliance

Excerpts of coverage: Bloomberg Bay State Biotech Report: Celgene’s New Agios Cancer Drug Deal: GEN - "Celgene and Agios Pharmaceuticals will partner to develop metabolic immuno-oncology therapies, under a strategic alliance that could generate about $1 billion-plus for Agios.The companies said they will discover, develop, and commercialize new treatments focused on altering the [...]

May 18th, 2016|

Boston is #1: GEN’s Annual “Top 10 U.S. Biopharma Clusters”

GEN has put out its annual "Top 10 U.S. Biopharma Clusters" list, and the regions of Big3Bio help lead the way, with the Greater Boston area again coming in at #1. The ranking criteria: NIH funding—Taken from the publicly available NIH RePORT database, for the current federal fiscal year, from its start on October 1, 2015, through [...]

May 2nd, 2016|

Why I’m Sticking With Sarepta

From CNBC: "Shares of Sarepta Pharmaceutical sinking after the FDA rejected the company's experimental drug to treat Muscular Dystrophy. Despite the drop, "Halftime Report" expert Jon Najarian is bullish on the stock long-term. Najarian sees the sell-off as a buying opportunity calling it "the gift that keeps on giving...I thought last week's selloff was overdone [...]

April 27th, 2016|

Intellia Plans IPO, Makes Deal With Regeneron

Coverage of Intellia's deal with Regeneron and IPO plans: BioFlash/BBJ: Cambridge gene-editing firm eyes IPO, discloses Novartis deal "The second of three local gene-editing firms has filed to go public with an offering that could rival or exceed the state’s largest so far among biotechs in 2016. Intellia plans to move into a new 65,000 square foot [...]

April 12th, 2016|

Big3Deal: Nimbus and Gilead

SFBay-area based Gilead Sciences has acquired Nimbus Apollo, Inc., a wholly-owned subsidiary of Cambridge, MA-based Nimbus Therapeutics, and its Acetyl-CoA Carboxylase (ACC) inhibitor program to treat nonalcoholic steatohepatitis (NASH) and possibly liver cancer and other diseases. Coverage of the deal: FierceBiotech: Gilead bags early-stage NASH drug in $1.2B Nimbus deal "Gilead is anteing up a $400 million up [...]

April 4th, 2016|

Paul Allen’s $100M Biotech Research Bet

With an initial commitment of $100 million, philanthropist and entrepreneur Paul G. Allen has created The Paul G. Allen Frontiers Group, whose purpose will be to “explore the landscape of bioscience and fund ideas at the frontier of knowledge to advance science and make the world better.” The Greater Boston, San Diego, and the San [...]

March 28th, 2016|

Early-Stage Biotech Funding at Risk

EP Vantage/Evaluate has published its Pharma & Biotech 2015 in Review and Medtech 2015 in Review reports and though 2015 boasted huge VC rounds for some, it also presented some bleak numbers for early-stage biopharma and med tech research companies seeking funding. Press release and two media takes with excerpts: Press Release “Early stage investment is the lifeblood of [...]

March 17th, 2016|